Aptose Biosciences Financials
APTO Stock | USD 0.19 0.01 5.56% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 0.74 | 0.779 |
|
|
Investors should never underestimate Aptose Biosciences' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Aptose Biosciences' cash flow, debt, and profitability to make informed and accurate decisions about investing in Aptose Biosciences.
Net Income |
|
Aptose | Select Account or Indicator |
Understanding current and past Aptose Biosciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Aptose Biosciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Aptose Biosciences' assets may result in an increase in income on the income statement.
Aptose Biosciences Stock Summary
Aptose Biosciences competes with CytomX Therapeutics, Instil Bio, Spero Therapeutics, Assembly Biosciences, and Fortress Biotech. Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada. Aptose Bioscns operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | CA03835T2002 |
CUSIP | 03835T200 03835T309 544192107 544191109 453219107 03835T101 |
Location | Ontario; Canada |
Business Address | 251 Consumers Road, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.aptose.com |
Phone | 647 479 9828 |
Currency | USD - US Dollar |
Aptose Biosciences Key Financial Ratios
Return On Equity | -6.94 | ||||
EBITDA | (52.27 M) | ||||
Net Income | (51.21 M) | ||||
Cash Per Share | 0.68 X | ||||
Debt To Equity | 0.01 % |
Aptose Biosciences Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 100.5M | 126.3M | 82.5M | 51.0M | 13.0M | 12.3M | |
Other Current Liab | 3.1M | 3.6M | 6.0M | 5.7M | 8.8M | 9.3M | |
Net Debt | (78.3M) | (116.3M) | (38.5M) | (35.7M) | (8.2M) | (8.6M) | |
Retained Earnings | (301.9M) | (357.2M) | (422.5M) | (464.3M) | (515.5M) | (489.8M) | |
Accounts Payable | 2.0M | 2.2M | 1.7M | 6.3M | 6.0M | 6.3M | |
Cash | 79.8M | 117.4M | 39.1M | 37.0M | 9.3M | 15.8M | |
Other Current Assets | 141K | 2.7M | 2.6M | 2.6M | 2.6M | 2.8M | |
Total Liab | 6.6M | 7.3M | 8.3M | 13.3M | 15.9M | 16.7M | |
Total Current Assets | 98.8M | 125.1M | 81.7M | 49.5M | 11.9M | 11.3M | |
Intangible Assets | 1.0 | 142.0 | 94.0 | 48.0 | 43.2 | 41.04 | |
Net Tangible Assets | 93.8M | 118.9M | 74.2M | 37.7M | 43.4M | 45.6M | |
Common Stock | 365.5M | 429.5M | 437.4M | 437.5M | 444.8M | 231.5M | |
Capital Surpluse | 34.6M | 50.9M | 63.7M | 68.9M | 79.2M | 51.4M | |
Net Invested Capital | 93.9M | 118.9M | 74.2M | 37.7M | (2.9M) | (2.8M) | |
Net Working Capital | 93.2M | 118.3M | 73.6M | 37.2M | (3.4M) | (3.2M) | |
Capital Stock | 365.5M | 429.5M | 437.4M | 437.5M | 444.8M | 435.6M |
Aptose Biosciences Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 574K | 522K | 92K | 770K | 885.5K | 929.8K | |
Gross Profit | (627.3K) | (646.4K) | (616.5K) | (507.1K) | (474.5K) | (450.8K) | |
Operating Income | (26.9M) | (55.8M) | (65.4M) | (42.6M) | (52.4M) | (49.7M) | |
Ebit | (26.9M) | (58.2M) | (64.8M) | (40.2M) | (52.4M) | (49.7M) | |
Research Development | 16.8M | 29.3M | 46.0M | 28.1M | 36.8M | 38.6M | |
Ebitda | (26.3M) | (57.5M) | (64.2M) | (39.7M) | (52.3M) | (49.7M) | |
Income Before Tax | (26.3M) | (55.2M) | (65.4M) | (41.8M) | (51.2M) | (48.6M) | |
Net Income | (25.7M) | (54.7M) | (65.3M) | (41.1M) | (51.2M) | (48.6M) | |
Income Tax Expense | (580K) | (530K) | (93K) | (770K) | (3.0) | (2.85) | |
Cost Of Revenue | 627.3K | 646.4K | 616.5K | 507.1K | 474.5K | 498.3K | |
Interest Income | 574K | 522K | 94K | 788K | 1.4M | 1.5M | |
Net Interest Income | 574K | 522K | 94K | 788K | 1.4M | 1.5M |
Aptose Biosciences Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | 64.5M | 37.6M | (78.3M) | (2.1M) | (27.7M) | (26.3M) | |
Free Cash Flow | (21.7M) | (34.0M) | (43.5M) | (32.3M) | (44.6M) | (42.4M) | |
Depreciation | 613K | 614K | 622K | 528K | 466K | 654.2K | |
Capital Expenditures | 102K | 79K | 212K | 24K | 29K | 27.6K | |
Net Income | (26.3M) | (55.2M) | (65.4M) | (41.8M) | (51.2M) | (48.6M) | |
End Period Cash Flow | 79.8M | 117.4M | 39.1M | 37.0M | 9.3M | 15.8M | |
Other Non Cash Items | (55K) | (435K) | 7.0M | (551K) | 48.9K | 51.3K | |
Investments | (17.3M) | 12.7M | (35.0M) | 30.1M | 25.6M | 26.9M | |
Change To Netincome | 2.6M | 21.5M | 20.5M | 5.2M | 6.0M | 6.3M |
Aptose Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Aptose Biosciences's current stock value. Our valuation model uses many indicators to compare Aptose Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aptose Biosciences competition to find correlations between indicators driving Aptose Biosciences's intrinsic value. More Info.Aptose Biosciences is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Aptose Biosciences' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Aptose Biosciences' earnings, one of the primary drivers of an investment's value.Aptose Biosciences Systematic Risk
Aptose Biosciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Aptose Biosciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Aptose Biosciences correlated with the market. If Beta is less than 0 Aptose Biosciences generally moves in the opposite direction as compared to the market. If Aptose Biosciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Aptose Biosciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Aptose Biosciences is generally in the same direction as the market. If Beta > 1 Aptose Biosciences moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Aptose Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Aptose Biosciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Aptose Biosciences growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Aptose Biosciences December 14, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Aptose Biosciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Aptose Biosciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Aptose Biosciences based on widely used predictive technical indicators. In general, we focus on analyzing Aptose Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Aptose Biosciences's daily price indicators and compare them against related drivers.
Information Ratio | (0.17) | |||
Maximum Drawdown | 33.33 | |||
Value At Risk | (7.69) | |||
Potential Upside | 5.56 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptose Biosciences. If investors know Aptose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptose Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.92) | Return On Assets (1.36) | Return On Equity (6.94) |
The market value of Aptose Biosciences is measured differently than its book value, which is the value of Aptose that is recorded on the company's balance sheet. Investors also form their own opinion of Aptose Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Aptose Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptose Biosciences' market value can be influenced by many factors that don't directly affect Aptose Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptose Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptose Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptose Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.